Fresenius Medical Care has achieved its targets for the financial year 2012.
Net revenue of Fresenius Medical Care AG & Co. KGaA for the full year 2012 was $13,800 million, up by 10% from the full year 2011.
Operating income (EBIT) for the full year 2012 increased by 7% to $2,219 million compared to $2,075 million for the full year 2011. Excluding one-time costs the operating income for the full year 2012 increased by 12% to $2,329 million.
For the full year 2012, net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA was $1,187 million, up 11% from the full year 2011. Excluding a positive non-taxable investment gain in the amount of $140 million and one-time costs in the amount of $71 million, net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA was $1,118 million, an increase of 4% compared to 2011.
For the 16th consecutive year shareholders can expect to receive an increased annual dividend. At the Annual General Meeting to be held on May 16, 2013, shareholders will be asked to approve a dividend per ordinary share of €0.75, an increase of 9% (2011: €0.69).
For the full year 2013, Fresenius Medical Care expects revenue to grow to more than $14.6 billion. Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA is expected to be between $1.1 and $1.2 billion. Based on the net income for 2012 excluding the investment gain, the expected earnings growth in 2013 is between 5% and 15%.
Fresenius SE & Co. KGaA (WKN 578560) holds 30.77% of Fresenius Medical Care AG & Co. KGaA’s capital.
Fresenius Medical Care AG & Co. KGaA
Represented by Fresenius Medical Care Management AG
Represented by its Management Board
Bad Homburg v.d.H., February 26, 2013
Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2.2 million individuals worldwide. Through its network of 3,160 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 257,916 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release